QuidelOrtho Corporation (QDEL) Price Prediction 2026–2050

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases.

The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use.

It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

QuidelOrtho Corporation, ticker QDEL, is categorized in Healthcare and operates as a diagnostics provider. As of now, the stock trades with a current price of $18.23 and a market cap of $1.24B, ranking 2293 by size. The price outlook shows a path of potential upside over the coming years, with year-by-year averages progressing from $18.23 in 2026 to higher levels through 2050, including notable increases to $49.66 by 2040 and $96.71 by 2050, reflected in rising average forecasts and double-digit to triple-digit ROI in later years.

The forecast highlights a sequence of annual averages and returns, beginning with 2026 average of $18.23 (ROI 0, sentiment NEUTRAL) and extending through 2030 ($21.27 average, ROI 16.7%), 2040 ($49.66 average, ROI 172.4%), and 2050 ($96.71 average, ROI 430.5%), with sentiment turning more bullish in later years. These figures illustrate a long-term growth trajectory while acknowledging that some years show lower or fluctuating averages.

The multi-year forecast shows meaningful upside in the longer horizons. By 2030, the average price is projected to $21.27 with a 16.7% ROI and a NEUTRAL sentiment. By 2040, the average rises to $49.66 with a 172.4% ROI and a BULLISH sentiment, and by 2050, the average is projected at $96.71 with a 430.5% ROI and a BULLISH sentiment.

Max forecast values over the period also reflect substantial upside: 2031 max $47.33, 2032 max $58.73, 2033 max $69.69, 2034 max $66.05, 2035 max $59.80, 2040 max $108.26, and 2050 max $222.42. These figures illustrate a trajectory of stronger upside in the longer term, albeit with variability and no guarantees.

Risks include year-to-year variability in averages (for example, 2029 avg $21.03 vs 2028 $24.81) and the possibility that forecasts do not materialize. The outlook should be interpreted as estimates, not guarantees, and not as financial advice.